Dry Eye Syndromes Clinical Trial
— DREAMOfficial title:
Clinical Trial of Essential Fatty Acids for Dry Eye Disease: Feasibility Study
Verified date | July 2012 |
Source | Asbell, Penny, M.D. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to test a protocol investigating the efficacy of omega-3 fatty acids in treating dry eye disease. The study is termed "feasibility" because its purpose is to demonstrate an ability to execute the proposed protocol with compliance at two sites rather than generate statistically relevant data concerning the safety and efficacy of the supplement in patients with dry eye disease.
Status | Completed |
Enrollment | 23 |
Est. completion date | March 2011 |
Est. primary completion date | July 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: 1. Sign and date the informed consent form approved by the IRB. 2. = 18 years of age 3. Demonstrate at least 2 of the 4 following signs in the same eye at two consecutive visits (Visit 1: 7 - 21 days prior to randomization, and Visit 2: day of randomization). 1. Conjunctival staining present = 1 2. Corneal fluorescein staining present = 1 3. Tear film break up time (TFBUT) = 7 seconds 4. Schirmer test = 7 mm/5min 4. Demonstrate symptoms of dry eye disease (OSDI score of at least 22 at screening visit and at least 15 at randomization visit). 5. Use or desire to use artificial tears on average of 2 times per day in the 2 weeks preceding study entry (run in period). No newly diagnosed patients can be enrolled and if a new patient wants to participate, she/he must be put on tears and re-evaluated in 6 months. 6. Intraocular pressure (IOP) = 5 mmHg and = 22 mmHg in each eye. 7. Women of child-bearing potential must agree to use a reliable method of contraception during study participation, and must demonstrate a negative urine pregnancy test at screening visit. 8. Be willing/able to return for all study visits and to follow instructions from the study investigator and his/her staff. 9. Be able to swallow large, soft gelcaps Exclusion Criteria: 1. Patients who are allergic to ingredients of the active or placebo pills (fish, olive oil). 2. Current diagnosis of ocular infection (e.g. bacterial, viral or fungal). 3. History of ocular herpetic keratitis. 4. Eye surgery (including cataract surgery) within 6 months prior to randomization. 5. Previous LASIK surgery 6. Pregnant or nursing/lactating 7. Participation in a study of an investigational drug or device within the past 30 days. 8. Recent (= 3 months) initiation of use of systemic corticosteroids or other immunosuppressive agent and/or is planning to change treatment during study participation 9. Cognitive or psychiatric deficit that precludes informed consent or ability to perform requirements of the investigation. 10. Contact lens wearers 11. Use of glaucoma medication or history of surgery for glaucoma. 12. Recent (= 3 months) insertion of punctual plugs. 13. Using punctual plugs but unwilling to commit to their use for the duration of the study. 14. Unwilling to commit to same brand of artificial tears throughout the study. 15. Current use of EPA/DHA supplements in excess of 1 gram/day. 16. Recent (= 6 months) initiation of use of Restasis. 17. Use of Restasis but unwilling to commit to use of Restasis for the duration of the study. 18. Discontinued use of Restasis within the last 3 months. |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Mount Sinai School of Medicine | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Asbell, Penny, M.D. | National Eye Institute (NEI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change on Ocular Surface Disease Index (OSDI) | 90 +/- 14 days following initiation of drug regimen | Yes | |
Primary | Change in REd Blood Cell(RBC) Membrane Fatty Acid(FA) Content | Baseline and 3 Months | No | |
Secondary | Change on Brief Ocular Discomfort Inventory (BODI) | 90 +/- 14 days following initiation of drug regimen | Yes | |
Secondary | Change on Impact of Dry Eye on Everyday Life (IDEEL) | 90 +/- 14 days following initiation of drug regimen | Yes | |
Secondary | Change in Quality of Life Associated With Chronic Pain | 90 +/- 14 days following initiation of drug regimen | Yes | |
Secondary | Change in the Ocular Surface | 90 +/- 14 days following initiation of drug regimen | Yes | |
Secondary | Change in Schirmer's | 90 +/- 14 days following initiation of drug regimen | Yes | |
Secondary | Change in Relevant Biomarkers: HLA-DR, MUC 5A, Cytokines | 90 +/- 14 days following initiation of drug regimen | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
Not yet recruiting |
NCT06379685 -
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
|
Phase 1 | |
Recruiting |
NCT04701086 -
3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis
|
N/A | |
Active, not recruiting |
NCT03697876 -
Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel
|
Phase 1 | |
Completed |
NCT02910713 -
Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
|
N/A | |
Terminated |
NCT02815293 -
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
|
Phase 3 | |
Completed |
NCT04104997 -
A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers
|
Phase 1 | |
Recruiting |
NCT02595606 -
0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients
|
Phase 4 | |
Completed |
NCT01711424 -
An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease
|
N/A | |
Completed |
NCT01015209 -
Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers
|
Phase 1 | |
Completed |
NCT01202747 -
Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction
|
Phase 2/Phase 3 | |
Completed |
NCT00969280 -
Acupuncture for Dry Eye Syndrome
|
Phase 3 | |
Completed |
NCT00739713 -
Effects of Sea Buckthorn Oil on Dry Eye
|
N/A | |
Completed |
NCT01496482 -
Comparison of Evaporimetry With the Established Methods of Tear Film Measurement
|
N/A | |
Completed |
NCT00756678 -
Efficacy and Acceptability of Two Lubricant Eye Drops
|
Phase 4 | |
Completed |
NCT00370747 -
Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome
|
Phase 2 | |
Completed |
NCT00349440 -
Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy
|
Phase 4 | |
Completed |
NCT05162261 -
to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction
|
N/A | |
Completed |
NCT02871440 -
A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye
|
Phase 3 | |
Completed |
NCT05042960 -
Computer Screen Properties Study
|
N/A |